Welcome!

News Feed Item

Nuvo Research® announces 2014 second quarter results

MISSISSAUGA, ON, July 30, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the second quarter ended June 30, 2014.

WF10 Phase 2 Clinical Trial Update
The enrolment for the Phase 2 WF10 clinical trial for the treatment of allergic rhinitis commenced in March 2014 and to-date, 121 patients have been enrolled at 15 sites in Germany.  Enrolment was slower than anticipated due to a late onset to the allergy season in Germany.  The trial is a 160-subject, randomized, double blind, placebo-controlled, 4-arm multi-centre trial to assess the efficacy and safety of a regimen of five WF10 infusions for the treatment of patients with moderate to severe persistent allergic rhinitis.  The Company expects the study to be completed in late 2014 with top-line results available in the first quarter of 2015.

Table of Selected Financial Results
For further details on the results, please refer to Nuvo's Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements which are available on the Company's website (www.nuvoresearch.com).

    Three months ended   Six months ended
    June 30,
2014
  June 30,
2013
  Change   June 30,
2014
  June 30,
2013
  Change
(Canadian dollars in thousands,
except per share and share figures)
  $   $   $   $   $   $
Revenue   3,863   3,320   543   6,620   5,571   1,049
Operating Expenses   6,034   5,624   410   11,677   11,040   637
Net loss   (2,307)   (2,220)   (87)   (5,050)   (5,490)   440
Per share - basic and diluted   (0.23)   (0.25)       (0.53)   (0.63)    

Q2 Financial Highlights
Revenue, consisting of product sales, royalties, license fee revenue and research and other contract revenue for the three months ended June 30, 2014 was $3.9 million compared to $3.3 million for the three months ended June 30, 2013.  The increase was attributable to higher product sales of Pennsaid 2% to support the launch in the U.S. and higher Pennsaid product sales to our distributors outside of the U.S.  Total revenue for the six months ended June 30, 2014 was $6.6 million compared to $5.6 million in the comparative period.

Total operating expenses for the three months ended June 30, 2014 increased to $6.0 million from $5.6 million for the three months ended June 30, 2013.  The increase was primarily due to higher General and Administrative (G&A) costs in the quarter.  Total operating expenses for the six months ended June 30, 2014 increased to $11.7 million from $11.0 million in the comparative period.

Cost of Goods Sold (COGS) was unchanged at $1.5 million for the three months ended June 30, 2014 and June 30, 2013.  The Company's gross margin on product sales increased to $0.7 million compared to $0.2 million in the comparative period, due to an increase in Pennsaid and Pennsaid 2% product sales in the quarter.  Gross margin as a percent of product sales increased in the quarter to 32% from 9% in the comparative period.  For the six months ended June 30, 2014, COGS increased to $2.7 million compared to $2.5 million for the six month ended June 30, 2013.

Research and Development expenses were unchanged at $1.5 million and $3.4 million for the three and six months ended June 30, 2014 and June 30, 2013.  In the quarter, the costs associated with the Company's Phase 2 clinical trial for WF10 were offset by the savings realized from the closure of the Company's facility in Salt Lake City and the TPT Group office in 2013.

G&A expenses were $2.9 million for the three months ended June 30, 2014 compared to $2.3 million for the three months ended June 30, 2013.  The increase in the quarter related to an increase in stock-based compensation and professional fees related to the Company's litigation with Mallinckrodt, partially offset by a decrease in non-cash charges related to amortization of the Company's intangible assets.  G&A expenses for the six months ended June 30, 2014 were $5.3 million compared to $4.6 million for the six months ended June 30, 2013.

Net loss was $2.3 million for the three months ended June 30, 2014 compared to $2.2 million for the three months ended June 30, 2013.  The increase in revenue in the quarter was offset by higher operating expenses and a foreign currency loss in the quarter compared to a foreign currency gain in the comparative period.  Net loss was $5.1 million for the six months ended June 30, 2014 compared to $5.5 million for the six months ended June 30, 2013.

Cash and cash equivalents were $10.7 million as at June 30, 2014 compared to $12.6 million as at December 31, 2013.

Cash used in operating activities increased to $2.7 million for the three months ended June 30, 2014 compared to $2.0 million for the three months ended June 30, 2013.  The increase was primarily due to higher investment in non-cash working capital in the quarter related to an increase in accounts receivable due to greater Pennsaid and Pennsaid 2% product sales.  For the six months ended June 30, 2014, cash used in operating activities was $3.6 million compared to $3.8 million for the six months ended June 30, 2013.

Net cash used in financing activities totaled $0.7 million for the three months ended June 30, 2014 compared to $0.5 million for the three months ended June 30, 2013. During both periods, the Company made repayments on finance, lease and other obligations.  Net cash provided by financing activities totaled $1.7 million for the six months ended June 30, 2014 compared to net cash used in financing activities of $0.9 million for the six months ended June 30, 2013.

The number of common shares outstanding as at June 30, 2014 was 10,239,619.

Pennsaid and Pennsaid 2% in the U.S.
According to IMS Health, a provider of dispensed prescription data, during the second quarter of 2014, U.S. prescriptions of Pennsaid 2% were 18,000 with an average of 1.23 bottles per script compared to 6,000 prescriptions in the first quarter of 2014.  Pennsaid 2% was launched on February 10, 2014.  Pennsaid prescriptions were 14,000 in the three months ended June 30, 2014, a 42% decrease from the prescriptions in the first quarter of 2014. The decrease in Pennsaid prescriptions was related to the launch of Pennsaid 2% as Mallinckrodt is working to switch the market from Pennsaid to Pennsaid 2% and the launch of a generic version of Pennsaid in the U.S. in May 2014.

About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies.  The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group.  The TPT Group has four U.S. Food and Drug Administration (FDA) approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin.  The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders.  For additional company information visit www.nuvoresearch.com.

Forward-Looking Statements
Certain statements in this news release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to the Company's anticipated use of proceeds from the Private Placement, the Company's future share price and the Company's possible election to accelerate the expiry date of any of the warrants or the brokers warrants and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "should", "plans" or "continue", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include general business and economic uncertainties and adverse market conditions as well as other risk factors included in the Company's Annual Information Form dated February 20, 2014 under the heading "Risks Factors" and as described from time to time in the reports and disclosure documents filed by the Company with Canadian securities regulatory agencies and commissions. This list is not exhaustive of the factors that may impact the Company's forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. The factors underlying current expectations are dynamic and subject to change. Although the forward-looking information contained in this news release is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.  All forward-looking statements in this news release are qualified by these cautionary statements. The forward-looking statements contained herein are made as of the date of this news release and except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.  

SOURCE Nuvo Research Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...